Review
Medicine, General & Internal
Andre Ramon, Helene Greigert, Paul Ornetti, Jean-Francis Maillefert, Bernard Bonnotte, Maxime Samson
Summary: Polymyalgia rheumatica (PMR) is an inflammatory rheumatism that affects the shoulder and pelvic girdles. There is often an association between PMR and giant cell arteritis (GCA), which can lead to severe vascular complications. Diagnosing GCA in patients with PMR is challenging, especially when it is subclinical. Clinical features such as new onset temporal headaches, glucocorticoids' resistance and constitutional symptoms can help predict the presence of GCA in PMR patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, Research & Experimental
Antonio Giovanni Solimando, Angelo Vacca, Franco Dammacco
Summary: Giant cell arteritis, polymyalgia rheumatica, and Takayasu's arteritis are characterized by extensive vascular remodeling resulting in occlusion and stenosis. Despite hypothetical pathophysiological mechanisms, similarities and differences in immunopathology and clinical phenotypes suggest a potential link between these diseases.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Rheumatology
Eugenio De Miguel, Pierluigi Macchioni, Edoardo Conticini, Corrado Campochiaro, Rositsa Karalilova, Sara Monti, Cristina Ponte, Giulia Klinowski, Irene Monjo-Henry, Paolo Falsetti, Zguro Batalov, Alessandro Tomelleri, Alojzija Hocevar
Summary: The objective of this study was to analyze the prevalence and characteristics of subclinical giant cell arteritis (GCA) in patients with polymyalgia rheumatica (PMR). The researchers used ultrasound to examine multiple arteries of PMR patients and found some of them had subclinical GCA. Patients with subclinical GCA were older, had longer morning stiffness duration, and more frequently reported hip pain compared to those without subclinical GCA. The optimal screening strategy to detect vasculitis in PMR needs further investigation.
Article
Immunology
Rosanne D. Reitsema, Bernd-Cornel Hesselink, Wayel H. Abdulahad, Kornelis S. M. van der Geest, Elisabeth Brouwer, Peter Heeringa, Yannick van Sleen
Summary: This study found differential phenotypes of antigen-presenting cells (APCs) in the peripheral blood of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) patients. The proportions of plasmacytoid DCs (pDCs) and CD141+ conventional DCs (cDC1) were lower in GCA/PMR, while the proportion of CD1c+ conventional DCs (cDC2) was negatively correlated with CRP. Additionally, single cell RNA sequencing identified differentially expressed genes related to inflammation and metabolism in GCA patients' APCs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Kresten Krarup Keller, Chetan B. Mukhtyar, Andreas Wiggers Nielsen, Andrea Katharina Hemmig, Sarah Louise Mackie, Sebastian Eduardo Sattui, Ellen-Margrethe Hauge, Anisha Dua, Toby Helliwell, Lorna Neill, Daniel Blockmans, Valerie Devauchelle-Pensec, Eric Hayes, Annett Jansen Venneboer, Sara Monti, Cristina Ponte, Eugenio De Miguel, Mark Matza, Kenneth J. Warrington, Kevin Byram, Kinanah Yaseen, Christine Peoples, Michael Putman, Lindsay Lally, Michael Finikiotis, Simone Appenzeller, Ugo Caramori, Carlos Enrique Toro-Gutierrez, Elisabeth Backhouse, Maria Camila Guerrero Oviedo, Victor Roman Pimentel-Quiroz, Helen Isobel Keen, Claire Elizabeth Owen, Thomas Daikeler, Annette de Thurah, Wolfgang A. Schmidt, Elisabeth Brouwer, Christian Dejaco
Summary: This study developed the first international recommendations for referral of individuals with suspected polymyalgia rheumatica (PMR), complementing the management guidelines for established PMR by the European Alliance of Associations for Rheumatology/American College of Rheumatology.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Idil Esen, Suzanne Arends, Berit Dalsgaard Nielsen, Philip Therkildsen, Ib Hansen, Anna van't Ende, Peter Heeringa, Annemieke Boots, Ellen Hauge, Elisabeth Brouwer, Yannick van Sleen
Summary: A study found that treatment-naive patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) had metabolic dysregulation before treatment, while long-term use of glucocorticoids (GCs) resulted in increased comorbidities and a poorer metabolic profile.
Review
Immunology
Miguel A. A. Gonzalez-Gay, Esther F. F. Vicente-Rabaneda, Juan A. A. Martinez-Lopez, Raquel Largo, Elena Heras-Recuero, Santos Castaneda
Summary: Polymyalgia rheumatica (PMR) is a relatively common condition in Western countries. It can be diagnosed in people over 50 years of age with sudden onset of pain and stiffness in the shoulder and hip girdles along with inflammation biomarkers elevation. However, it is important to consider the possibility of associated giant cell arteritis (GCA) or other conditions mimicking PMR.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Amir Emamifar, Torkell Ellingsen, Anne Pernille Hermann, Soren Hess, Oke Gerke, Ziba Ahangarani Farahani, Per Syrak Hansen, Inger Marie Jensen Hansen, Peter Thye-Ronn
Summary: The study revealed that in the treatment process of patients with PMR/GCA, arterial stiffness decreased, and body composition changed, with a decrease in bone mineral content and an increase in fat mass, while lean body mass did not significantly change.
SCIENTIFIC REPORTS
(2021)
Article
Rheumatology
Eugenio De Miguel, Rositsa Karalilova, Pierluigi Macchioni, Cristina Ponte, Edoardo Conticini, Sharon Cowley, Alessandro Tomelleri, Sara Monti, Irene Monjo, Zguro Batalov, Giulia Klinowski, Paolo Falsetti, David J. Kane, Corrado Campochiaro, Alojzija Hocevar
Summary: The aim of this study was to assess the clinical significance of subclinical giant cell arteritis (GCA) in polymyalgia rheumatica (PMR) and determine the optimal treatment approach. Results showed that PMR patients with subclinical GCA had a higher rate of relapse during a 2-year follow-up compared to those with isolated PMR. Lower starting doses of glucocorticoids and rapid tapering within the first 3 months were identified as risk factors for relapse.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Yannick van Sleen, Kornelis S. M. van der Geest, Rosanne D. Reitsema, Idil Esen, Janneke H. Terpstra, Elisabeth Raveling-Eelsing, Marieke van der Heiden, Thomas Lieber, Annemarie M. Buisman, Debbie van Baarle, Maria Sandovici, Elisabeth Brouwer
Summary: The study found that SARS-CoV-2 vaccination was safe for GCA/PMR patients and their immune response to the vaccine was comparable to other older individuals. Patients using methotrexate and particularly >10 mg/day prednisolone had lower vaccine responses, potentially increasing their risk of breakthrough SARS-CoV-2 infection.
Review
Immunology
Eric Liozon, Simon Parreau, Matthieu Filloux, Stephanie Dumonteil, Guillaume Gondran, Holy Bezanahary, K. H. Ly, Anne Laure Fauchais
Summary: This study found that post-IV onset of GCA/PMR is not rare, especially in individuals at higher spontaneous risk such as those with personal or familial history of GCA/PMR. Post-IV PMR generally appeared self-limited, while post-IV GCA often displayed a more protracted course.
AUTOIMMUNITY REVIEWS
(2021)
Article
Rheumatology
Andrea K. Hemmig, Markus Aschwanden, Christoph T. Berger, Diego Kyburz, Noemi Mensch, Daniel Staub, Mihaela Stegert, Stephan Imfeld, Thomas Daikeler
Summary: The presence of prior polymyalgia rheumatica (PMR) in patients with giant cell arteritis (GCA) is associated with a more severe and damaging disease course. PMR is specifically associated with large vessel vasculitis and vascular stenosis in GCA patients.
Article
Rheumatology
Keziah Austin, Emma Dures, Celia Almeida, Fiona Cramp, Catherine M. Guly, Catherine L. Hill, Elizabeth A. Hoon, Sarah Mackie, Anne O'Brien, Richard A. Watts, Joanna C. Robson
Summary: The study identified a range of barriers and facilitators to physical activity in giant cell arteritis (GCA) patients, including physical symptoms, perceptions of personal capability, negative perceptions of physical activity, and facilitators such as motivation from healthcare professionals and personal strategies like pacing and goal-setting. Future work could involve developing an intervention to support physical activity in GCA patients, potentially using a behavioral change framework and involving patients in the design process.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Clinical Neurology
Andrew N. Bubak, Teresa Mescher, Michael Mariani, Seth E. Frietze, James E. Hassell, Christy S. Niemeyer, Christina N. Como, Anna M. Burnet, Prem S. Subramanian, Randall J. Cohrs, Ravi Mahalingam, Maria A. Nagel
Summary: VZV antigen was detected in temporal arteries of GCA patients, suggesting a potential role for virus infection in GCA pathogenesis. RNA sequencing revealed enrichment of viral infection pathways and immune activation in GCA TAs, while control samples also showed viral pathways and vascular remodeling processes, indicating early infection progression.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Clinical Neurology
Carolin Beuker, Maximilian Christian Wankner, Christian Thomas, Jan-Kolja Strecker, Antje Schmidt-Pogoda, Wolfram Schwindt, Andreas Schulte-Mecklenbeck, Catharina Gross, Heinz Wiendl, Peter J. Barth, Bernd Eckert, Thomas Raphael Meinel, Marcel Arnold, Jens Schaumberg, Schulamith Krueger, Milani Deb-Chatterji, Tim Magnus, Joachim Roether, Jens Minnerup
Summary: This study aimed to characterize patients with extracranial giant cell arteritis with intracranial involvement. Findings showed that typical characteristics of GCA such as headache and elevated ESR were frequently absent in patients with intracranial involvement, but the pattern of vertebral artery stenosis could help differentiate GCA from atherosclerosis. Approximately one-third of patients with intracranial GCA had a rapid progressive disease course, and IL-17 and IL-6 may represent potential future treatment targets.
ANNALS OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Tajana Tesan Tomic, Josefin Olausson, Annica Wilzen, Magnus Sabel, Katarina Truve, Helene Sjogren, Sandor Dosa, Magnus Tisell, Birgitta Lannering, Fredrik Enlund, Tommy Martinsson, Pierre Aman, Frida Abel
Article
Genetics & Heredity
Soheila Dolatabadi, Julian Candia, Nina Akrap, Christoffer Vannas, Tajana Tesan Tomic, Wolfgang Losert, Goran Landberg, Pierre Aman, Anders Stahlberg
FRONTIERS IN GENETICS
(2017)
Article
Medicine, Research & Experimental
David Svec, Soheila Dolatabadi, Christer Thomsen, Nicole Cordes, Mark Shannon, Paul Fitzpatrick, Goeran Landberg, Pierre Aman, Anders Stahlberg
LABORATORY INVESTIGATION
(2018)
Article
Oncology
Soheila Dolatabadi, Emma Jonasson, Malin Linden, Bentolhoda Fereydouni, Karin Backsten, Malin Nilsson, Anna Martner, Amin Forootan, Henrik Fagman, Goran Landberg, Pierre Aman, Anders Stahlberg
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Medicine, Research & Experimental
Marcel Trautmann, Ya-Yun Cheng, Patrizia Jensen, Ninel Azoitei, Ines Brunner, Jennifer Huellein, Mikolaj Slabicki, Ilka Isfort, Magdalene Cyra, Ruth Berthold, Eva Wardelmann, Sebastian Huss, Bianca Altvater, Claudia Rossig, Susanne Hafner, Thomas Simmet, Anders Stahlberg, Pierre Aman, Thorsten Zenz, Undine Lange, Thomas Kindler, Claudia Scholl, Wolfgang Hartmann, Stefan Froehling
EMBO MOLECULAR MEDICINE
(2019)
Article
Oncology
Marcel Trautmann, Magdalene Cyra, Ilka Isfort, Birte Jeiler, Arne Krueger, Inga Gruenewald, Konrad Steinestel, Bianca Altvater, Claudia Rossig, Susanne Hafner, Thomas Simmet, Jessica Becker, Pierre Amana, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann
MOLECULAR CANCER THERAPEUTICS
(2019)
Article
Biochemistry & Molecular Biology
Malin Linden, Christer Thomsen, Pernilla Grundevik, Emma Jonasson, Daniel Andersson, Rikard Runnberg, Soheila Dolatabadi, Christoffer Vannas, Manuel Luna Santamaria, Henrik Fagman, Anders Stahlberg, Pierre Aman
Review
Cell Biology
Mattias K. Andersson, Pierre Aman, Goran Stenman
Article
Multidisciplinary Sciences
Ilka Isfort, Sandra Elges, Magdalene Cyra, Ruth Berthold, Marcus Renner, Gunhild Mechtersheimer, Pierre Aman, Olle Larsson, Nancy Ratner, Susanne Hafner, Thomas Simmet, Christoph Schliemann, Claudia Rossig, Uta Dirksen, Inga Gruenewald, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann, Marcel Trautmann
SCIENTIFIC REPORTS
(2019)
Article
Cell Biology
Emma Jonasson, Lisa Andersson, Soheila Dolatabadi, Salim Ghannoum, Pierre Aman, Anders Stahlberg
Article
Oncology
Malin Linden, Christoffer Vannas, Tobias Osterlund, Lisa Andersson, Ayman Osman, Mandy Escobar, Henrik Fagman, Anders Stahlberg, Pierre Aman
Summary: FET fusion oncoproteins bind with SWI/SNF complexes and indirectly interact with BRD4, co-localizing on chromatin and interacting with transcription factors and RNA Polymerase II.
MOLECULAR ONCOLOGY
(2022)
Article
Oncology
Soheila Dolatabadi, Emma Jonasson, Lisa Andersson, Manuel Luna Santamaria, Malin Linden, Tobias Osterlund, Pierre Aman, Anders Stahlberg
Summary: Myxoid liposarcoma, a type of sarcoma characterized by FET fusion oncogenes, is associated with JAK-STAT signaling. In this study, the researchers found that the FET fusion oncogene FUS-DDIT3 is closely connected to JAK-STAT signaling. They identified genes regulated by both FUS-DDIT3 and JAK1/2 inhibition, and confirmed the targets using chromatin immunoprecipitation sequencing data sets. The findings provide new insights into the molecular mechanisms underlying tumor progression and potential avenues for targeted therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ruth Berthold, Ilka Isfort, Cihan Erkut, Lorena Heinst, Inga Gruenewald, Eva Wardelmann, Thomas Kindler, Pierre Aman, Thomas G. P. Gruenewald, Florencia Cidre-Aranaz, Marcel Trautmann, Stefan Froehling, Claudia Scholl, Wolfgang Hartmann
Summary: Myxoid liposarcoma (MLS), a common subtype of liposarcoma, is characterized by a recurrent chromosomal translocation generating a chimeric FUS-DDIT3 fusion gene. The study reveals that FUS-DDIT3-driven IGF-IR/PI3K/AKT signaling promotes stability and nuclear accumulation of YAP1 via deregulation of the Hippo pathway, and demonstrates substantial cooperative effects of YAP1 and FUS-DDIT3 in the pathogenesis of MLS.
Article
Biochemistry & Molecular Biology
Christoffer Vannas, Lisa Andersson, Soheila Dolatabadi, Parmida Ranji, Malin Linden, Emma Jonasson, Anders Stahlberg, Henrik Fagman, Pierre Aman
Summary: Research has shown that different HSP90 inhibitors can have significant differences in therapeutic effects and outcomes for myxoid liposarcoma, with some inhibitors even leading to paradoxical effects. Careful consideration should be given to drug selection and treatment strategies.
Article
Oncology
Marcel Trautmann, Jasmin Menzel, Christian Bertling, Magdalene Cyra, Ilka Isfort, Konrad Steinestel, Sandra Elges, Inga Guenewald, Bianca Altvater, Claudia Rossig, Stefan Froehling, Susanne Hafner, Thomas Simmet, Pierre Aman, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann
CLINICAL CANCER RESEARCH
(2017)